Trials / Completed
CompletedNCT00970970
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Visualizing VEGF Producing Lesions in Von Hippel-Lindau Disease
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 22 (actual)
- Sponsor
- University Medical Center Groningen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Von Hippel Lindau disease (VHLD) is an inherited syndrome characterized by vascular malformations, kidney cancer, adrenal gland and pancreas tumors. The VHL protein is not functional in the different disease associated lesions which results in production of high amounts of vascular endothelial growth factor (VEGF). Currently there are no clinical, radiographic or molecular markers that can predict the natural history of a given lesion. With 89Zr-bevacizumab positron emission tomography (PET) scanning, VEGF can be visualized and quantified. The investigators hypothesize that 89Zr-bevacizumab PET imaging is a useful tool to predict the behaviour of disease associated lesions in patients with VHLD. Adult patients with VHLD who have had routine magnetic resonance imaging (MRI) scans of central nervous system (CNS) and abdomen will undergo a 89Zr-bevacizumab PET scan. MRI will be repeated within 12 months.
Conditions
- Von Hippel-Lindau Disease
- Hemangioblastoma
- Renal Cell Carcinoma
- Pheochromocytoma
- Pancreatic Neuroendocrine Tumor
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | 89Zr bevacizumab PET scan | Patients will be injected intravenously with 37 MBq, protein dose 5 mg 89Zr-bevacizumab at day 0. PET scans will be done at day 4. |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2009-09-03
- Last updated
- 2024-05-06
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00970970. Inclusion in this directory is not an endorsement.